India  
NewsR.in
> >

House Democrats May Investigate Soaring Drug Costs

Video Credit: Newsy Studio - Duration: 02:17s - Published < > Embed
House Democrats May Investigate Soaring Drug Costs

House Democrats May Investigate Soaring Drug Costs

Incoming House oversight committee Chairman Elijah Cummings says he may look at soaring drug prices in the next Congress.

0
shares
ShareTweetSavePostSend
 

House Democrats May Investigate Soaring Drug Costs

There's been a lot of talk about what House Democrats will investigate when they take control in January.

And while the Trump administration has been getting most of the attention, there's another target up for congressional investigation: big pharma.

Incoming House oversight committee Chairman Elijah Cummings says he plans to bring in pharmaceutical company CEOs to ask for details about skyrocketing drug costs.  Prescription drug prices have been on a significant rise over the last 25 years.

But according to Kaiser, from 2013- 2015 there was a large spike that has not seen a real decline.

Just this week, Pfizer announced it will raise prices of 41 of its drugs in January.

The company creates a wide range of drugs from Advil to the opioid overdose reversing drug naloxone.

Cummings has a long history battling with drug companies.

But now, as head of the committee, he'll have subpoena power and plans to use it to bring some of the heads of these companies in front of Congress.  This isn't new territory for the Maryland Democrat.

Back in 2016, he was part of the committee that wanted to know why the CEO of Mylan was raising the prices of EpiPens.

He also reprimanded a smirking Martin Shkreli at a 2016 hearing.

The entrepreneur, also known as the "pharma bro," had recently raised the price of an anti-malaria drug from $13.50 to $750 per pill.  Among the companies Cummings said he wants to focus on in 2019 is Allergan, a company that made a deal to shield itself from generic competition with its eye drops.  The incoming chairman says he wants to talk to CEOs about the cost of research and development.

Many companies have previously cited this expense as the reason for high drug prices.

But in the end, this committee doesn't create laws.

It only investigates.

So any findings will need to be turned into action somewhere else.

It may actually be something this Congress, and the president, can find common ground on.

Both sides have already generated legislative proposals, and President Trump has also said this is a top priority in his administration. 




You Might Like


Tweets about this


Recent related videos from verified sources

House Democratic Fight For HealthCare On All Fronts [Video]House Democratic Fight For HealthCare On All Fronts

Democratic leaders in the House gave their liberal lawmakers what they wanted on health care, and now it seems like they’re fighting to keep “Medicare for All“ from devouring the party. Politco..

Credit: Wochit     Duration: 00:49Published

Lawmakers from both parties push for lower drug prices in Wisconsin [Video]Lawmakers from both parties push for lower drug prices in Wisconsin

Wisconsin Democrats and Republicans are trying to lower prescription drug costs and provide consumers with more information about pricing.

Credit: WKBTPublished

Senators Attack Drug Company Executives [Video]Senators Attack Drug Company Executives

According to Reuters, U.S. Senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an..

Credit: Wochit News     Duration: 00:46Published

Maryland Democrats Outline Legislative Priorities [Video]Maryland Democrats Outline Legislative Priorities

Cutting prescription drug costs and ensuring health insurance coverage for people with pre-existing medical problems are some of the top priorities for Maryland Democrats this legislative session.

Credit: WJZ Baltimore     Duration: 00:37Published

Environmentally friendly: newsR is hosted on servers powered solely by renewable energy
© 2019 newsR Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest